1. Home
  2. ZGN vs WVE Comparison

ZGN vs WVE Comparison

Compare ZGN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ermenegildo Zegna N.V.

ZGN

Ermenegildo Zegna N.V.

HOLD

Current Price

$13.30

Market Cap

2.4B

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$6.35

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZGN
WVE
Founded
1910
2012
Country
Italy
Singapore
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.4B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
ZGN
WVE
Price
$13.30
$6.35
Analyst Decision
Buy
Strong Buy
Analyst Count
4
16
Target Price
$11.28
$29.81
AVG Volume (30 Days)
747.8K
4.2M
Earning Date
03-20-2026
04-28-2026
Dividend Yield
1.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
$5.17
N/A
Revenue Next Year
$7.89
$85.67
P/E Ratio
$25.94
N/A
Revenue Growth
N/A
149.43
52 Week Low
$7.61
$5.02
52 Week High
$13.50
$21.73

Technical Indicators

Market Signals
Indicator
ZGN
WVE
Relative Strength Index (RSI) 63.96 34.87
Support Level $9.89 $5.02
Resistance Level $13.38 $7.65
Average True Range (ATR) 0.44 0.38
MACD 0.02 0.01
Stochastic Oscillator 88.69 19.12

Price Performance

Historical Comparison
ZGN
WVE

About ZGN Ermenegildo Zegna N.V.

Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: